Skip to content
RXRX·Nasdaq·US

Recursion

Recursion is a clinical-stage biotechnology company that uses an AI-native platform to industrialize drug discovery and development. It generates revenue mainly from collaboration agreements, milestone payments, and related partnership economics with large pharmaceutical companies.

Thematic Position

RXRX

Relationship Groups

Partners6
Licensing2
Competitors3

Relationship details are part of the Pro plan.

Ended Relationships

9 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

export controlsanctionimport restriction
U.S. export controls and OFAC sanctions limit Recursion's international product and technology transfers
SEC 10-KFeb 25, 2026

The full regulatory passage is part of the Pro plan.

11 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

2 customers · Named major customers are part of the Pro plan.